within Pharmacolibrary.Drugs.ATC.L;

model L02AA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.004166666666666667,
    adminDuration  = 600,
    adminMass      = 0.24,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Polyestradiol phosphate (PEP) is a long-acting parenteral estrogen used primarily in the treatment of advanced prostate cancer in men. It acts as an estrogen receptor agonist, exerting anti-androgenic effects by suppressing testosterone production. Its clinical use has declined with the availability of more modern therapies, but may still be found in some regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult male patients with advanced prostate cancer, following intramuscular administration.</p><h4>References</h4><ol><li>R Stege, P O Gunnarsson, C J Johansson, P Olsson, A Pousette, K Carlström,Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients.,The Prostate,1996<a href='https://pubmed.ncbi.nlm.nih.gov/8610057/'>https://pubmed.ncbi.nlm.nih.gov/8610057/</a></li><li>P O Gunnarsson, B J Norlén,Clinical pharmacology of polyestradiol phosphate.,The Prostate,1988<a href='https://pubmed.ncbi.nlm.nih.gov/3217277/'>https://pubmed.ncbi.nlm.nih.gov/3217277/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L02AA02;
